Treatment of Cryptosporidium: What We Know, Gaps, and the Way Forward.
Treatment of Cryptosporidium: What We Know, Gaps, and the Way Forward.
复制标题
DOI：
10.1007/s40475-015-0056-9
复制
发表时间：
2015-09
影响因子：
5.4
通讯作者：
White AC Jr
中科院分区：
文献类型：
--
作者：
Sparks H;Nair G;Castellanos-Gonzalez A;White AC Jr
隐孢子虫病日益被认为是一个重要的全球卫生问题。隐孢子虫病最初是在免疫功能低下的艾滋病患者中报道的，现在已被证明是儿童腹泻的主要原因和儿童营养不良的一个重要因素。目前，nitazoxanide是唯一被证实的治疗隐孢子虫感染的抗寄生虫药物。然而，它对严重免疫功能低下的患者无效，而且在婴儿中的数据有限。免疫重建或减少免疫抑制对艾滋病和移植患者的治疗至关重要。鉴于疾病的沉重负担，这种治疗选择的有限性对公共卫生构成了重大挑战。针对其他适应症开发的药物的再利用和针对新靶点的抑制剂的开发为改进治疗提供了希望，但都没有进入临床研究。
Cryptosporidiosis is increasingly recognized as an important global health concern. While initially reported in immunocompromised such as AIDS patients, cryptosporidiosis has now been documented as a major cause of childhood diarrhea and an important factor in childhood malnutrition. Currently, nitazoxanide is the only proven anti-parasitic treatment for Cryptosporidium infections. However, it is not effective in severely immunocompromised patients and there is limited data in infants. Immune reconstitution or decreased immunosuppression is critical to therapy in AIDS and transplant patients. This limitation of treatment options presents a major public health challenge given the important burden of disease. Repurposing of drugs developed for other indications and development of inhibitors for novel targets offer hope for improved therapies, but none have advanced to clinical studies.